Pilot Study of the Human Metagenome in Metabolic Diseases
Understanding the Role of the Human Metagenome in Obesity, Metabolic Diseases, Chronic Inflammation, Sarcopenia and Sarcopenic Obesity - a Pilot Study
Sengkang General Hospital
600 participants
Aug 14, 2023
OBSERVATIONAL
Conditions
Summary
This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia. Recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing. We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.
Eligibility
Inclusion Criteria3
- Obese (BMI\>27.5kg/m2)
- Sarcopenic patients, defined as 1) low handgrip strength (\<26 for males; \<18kg for females), AND/OR low gait speed (\<0.8m/s) AND low muscle mass (\<7.0kg/m2 for males; \<5.7kg/m2 for females)
- \- Healthy subjects without sarcopenia, and not obese (BMI\<27.5kg/m2)
Exclusion Criteria2
- No informed consent
- Presence of intestinal stoma, hence inability to collect fecal samples
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group). Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention Control subjects will have no interventions performed as well.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06363253